Tonix Pharmaceuticals has achieved major pipeline and commercial milestones with the development and regulatory approval of Tonmya, formulated as cyclobenzaprine hydrochloride sublingual tablets intended for the management of fibromyalgia. Additionally, the enterprise has continuously announced preclinical and clinical advancements across its broader pipeline, targeting conditions such as post-traumatic stress disorder, long COVID, various infectious diseases, and specialized rare genetic disorders utilizing innovative sublingual and intranasal drug delivery technologies designed to improve patient compliance and pharmacokinetic profiles.